Caitong International Asset Management Co. Ltd decreased its holdings in shares of Revvity Inc. (NYSE:RVTY – Free Report) by 53.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 326 shares of the company’s stock after selling 368 shares during the quarter. Caitong International Asset Management Co. Ltd’s holdings in Revvity were worth $32,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the business. T. Rowe Price Investment Management Inc. grew its holdings in Revvity by 8.5% during the first quarter. T. Rowe Price Investment Management Inc. now owns 22,515,711 shares of the company’s stock valued at $2,382,163,000 after purchasing an additional 1,754,403 shares during the period. Vanguard Group Inc. grew its holdings in Revvity by 0.6% during the first quarter. Vanguard Group Inc. now owns 14,382,849 shares of the company’s stock valued at $1,521,705,000 after purchasing an additional 92,638 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Revvity by 25.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 9,563,911 shares of the company’s stock valued at $1,011,863,000 after purchasing an additional 1,932,314 shares during the period. EdgePoint Investment Group Inc. grew its holdings in Revvity by 32.1% during the first quarter. EdgePoint Investment Group Inc. now owns 5,360,847 shares of the company’s stock valued at $567,178,000 after purchasing an additional 1,302,616 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Revvity by 1.8% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,444,645 shares of the company’s stock valued at $364,443,000 after purchasing an additional 62,307 shares during the period. Institutional investors and hedge funds own 86.65% of the company’s stock.
Revvity Stock Performance
Shares of RVTY stock opened at $98.91 on Monday. The company’s fifty day simple moving average is $89.38 and its 200-day simple moving average is $92.37. The company has a quick ratio of 2.75, a current ratio of 3.33 and a debt-to-equity ratio of 0.43. The firm has a market cap of $11.48 billion, a PE ratio of 41.91, a P/E/G ratio of 3.30 and a beta of 0.98. Revvity Inc. has a 12 month low of $81.36 and a 12 month high of $129.50.
Revvity Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 6th. Stockholders of record on Friday, January 16th will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Friday, January 16th. Revvity’s payout ratio is currently 11.86%.
Wall Street Analysts Forecast Growth
RVTY has been the subject of a number of analyst reports. Barclays decreased their price objective on shares of Revvity from $110.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, October 2nd. Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 3rd. Weiss Ratings reiterated a “sell (d+)” rating on shares of Revvity in a report on Saturday. Stifel Nicolaus dropped their price objective on shares of Revvity from $120.00 to $110.00 and set a “hold” rating on the stock in a report on Tuesday, July 29th. Finally, Evercore ISI cut their price objective on shares of Revvity from $108.00 to $106.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 7th. Nine research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $116.38.
Read Our Latest Stock Report on RVTY
Revvity Profile
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Further Reading
- Five stocks we like better than Revvity
- What Are Dividend Champions? How to Invest in the Champions
- PulteGroup Is Down But Not Out—Here’s What Wall Street Missed
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Cleveland-Cliffs Breaks to New Highs on Earnings, More Upside?
- Buy P&G Now, Before It Sets A New All-Time High
- Is Landstar the Next Big Winner in Transportation Stocks?
Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity Inc. (NYSE:RVTY – Free Report).
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
